DCPH - Deciphera Pharma teams up with Medison Pharma to commercialize Qinlock in Canada and Israel

Medison Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals (DCPH) to commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor ((GIST)), a cancer that occurs in the gastrointestinal tract, mostly in stomach or small intestine. Medison Canada expects to launch QINLOCK in Q4 2020. Medison Israel is planning to submit QINLOCK for registration during Q1 2021 and commence an early access program ((EAP)) for Israeli patients immediately after.

For further details see:

Deciphera Pharma teams up with Medison Pharma to commercialize Qinlock in Canada and Israel